According to the Zhitong Finance App, Keji Pharmaceutical-B (02171.HK) announced its 2026 interim results, with revenue of about 61.919 million yuan, up 21.5% year on year; adjusted net loss of 31.927 million yuan, a year-on-year narrowing of 55.53%; parent company owners should account for a loss of 666.63 million yuan, a decrease of 11.52% year on year; loss per share of 0.13 yuan.

According to the Zhitong Finance App, Keji Pharmaceutical-B (02171.HK) announced its 2026 interim results, with revenue of about 61.919 million yuan, up 21.5% year on year; adjusted net loss of 31.927 million yuan, a year-on-year narrowing of 55.53%; parent company owners should account for a loss of 666.63 million yuan, a decrease of 11.52% year on year; loss per share of 0.13 yuan.